Advancing Therapeutic Paradigms for Ovarian Cancer in The Era of PARP Inhibitors: A Guide for The Oncology Nurse
To attend in person, please click the Register button above.
To attend via Zoom, please click here to register.
This symposium will explore the latest ovarian cancer guideline recommendations and recent evidence for PARP inhibitors in treatment and maintenance settings. The nurse’s role in facilitating access to quality care for those with disparities, the unique toxicity profiles of PARP inhibitors, and how to mitigate, anticipate, and manage toxicities that may arise will also be discussed. Attendees will interact with the expert faculty through patient cases with audience response questions incorporated throughout.
Meeting space has been assigned to provide a Symposia supported by GlaxoSmithKline and presented by Creative Educational Concepts during the Oncology Nursing Society’s (ONS) 47th Annual Congress, April 28–May 1, 2022 in Anaheim, CA. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.
Oncology Nurses and Nurse Practitioners attending the 2022 ONS Annual Congress who practice in areas across the United States where patients experience disparity in the treatment of ovarian cancer.
At the conclusion of this live activity, participants will gain the skills and/or knowledge to:
- Explore the latest guideline recommendations on ovarian cancer treatment and discuss patient disparities and barriers to receiving guideline recommended care.
- Appraise emerging efficacy trial data with PARP inhibitors in the frontline and recurrent maintenance treatment settings for ovarian cancer.
- Evaluate unique toxicities associated with PARP inhibitor therapy and analyze optimal strategies for the prevention, recognition, and treatment of adverse events.
- Using an interactive, case-based approach, discuss challenging cases regarding the use of PARP inhibitors and examine best practices for oncology nurses to optimize therapy, anticipate and manage adverse events, improve oral adherence and bridge the gap in care for those with socioeconomic and racial disparities.
Supported through an independent educational grant from GlaxoSmithKline.
Presented by Creative Educational Concepts, LLC.
10 minutes Welcome and Introductions/Pre-test
15 minutes Revisiting the Current Paradigm in Ovarian Cancer Treatment
30 minutes Current Data and Future Prospects of PARP Inhibitors in Ovarian Cancer
25 minutes Integrating Clinical Data into Clinical Practice—Interactive Case-based Treatment Strategies for the Oncology Nurse
10 minutes Conversations with the Experts: Audience Q&A/Post-test
Paula Anastasia, MN, RN, AOCN - Activity Chair
Advanced Practice Nurse
Los Angeles, California
Paula Anastasia, RN, MN, AOCN has been a GYN-Oncology Clinical Nurse Specialist for 29 years, and an oncology nurse for 39 years. She is currently working at UCLA Health in Los Angeles, CA. Her patient relationship begins with diagnosis, followed by education, genetic screening/assessment, clinical research trials, treatment, surveillance, recurrence, and palliative and end of life care.
Ms. Anastasia has numerous publications in peer reviewed nursing journals and book chapters, and is a national public speaker on ovarian cancer, chemotherapy symptom management, and survivorship issues. She is an Associate Editor for the Journal of the Advanced Practitioner in Oncology.
Ms. Anastasia received her MN from the University of California, Los Angeles and her BSN from Rush University, in Chicago. Her passion is educating both nurses and patients with cancer on how to improve life while living with a cancer diagnosis.
Jennifer Filipi, MSN, NP
Center for Gynecologic Oncology
Massachusetts General Hospital
Jenny Filipi is a Nurse Practitioner at Massachusetts General Hospital in the Department of Gynecologic Oncology. She received her BS in Exercise Physiology from Ohio State University. After moving to Boston, she attended nursing school and ultimately received her MS in Nursing from Regis College in Massachusetts. She is a member of the Boston ONS chapter, where she has served as Director at Large in the past.
Shannon N. Westin, MD, MPH
Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery
The University of Texas MD Anderson Cancer Center
Dr. Westin received her doctorate of Medicine from the University of Florida College of Medicine. She completed Obstetrics and Gynecology residency at the University of North Carolina – Chapel Hill and fellowship in Gynecologic Oncology at the University of Texas MD Anderson Cancer Center. During her fellowship, she received an MPH with a concentration in epidemiology from the University of Texas, School of Public Health. In addition to her training in Gynecologic Oncology, she also completed a short fellowship in Investigational Cancer Therapeutics. She joined the faculty at The University of Texas MD Anderson Cancer Center in 2010. She has been honored as a K12 scholar, an Andrew Sabin Family Fellow, and a Gynecologic Oncology Group (GOG) Foundation Scholar Investigator.
Dr. Westin focuses on developmental therapeutics and the use of biomarkers to predict response and recurrence in gynecologic malignancies. She currently serves as the Director of Early Drug Development and Phase I Trials in her department and is a Co-Director of the Ovarian Cancer Moonshot. Dr. Westin is a member of the NRG Oncology – GOG Developmental Therapeutics, Phase I, and Early Phase Protocol Oversight committees. She is the co-PI for five major projects in her institution’s SPORE in Uterine Cancer and SPORE in Ovarian Cancer. In addition, she is currently the PI or co-PI for greater than 30 novel treatment trials in gynecologic malignancies.
Dr. Westin has authored or co-authored greater than 150 scientific publications, book chapters and invited articles. She has been invited to lecture as an expert on clinical trials, genomic testing and targeted therapy in gynecologic malignancies in national and international venues. She was selected for the competitive American Society of Clinical Oncology (ASCO) Leadership Development program and serves on five ASCO committees including the Communications Committee and Gynecologic Cancer Guidelines Group. She currently serves on the Board of Directors for the Society of Gynecologic Oncology (SGO) and the GOG Foundation. In addition to serving on the National Cancer Institute (NCI) Uterine Task Force and Gynecologic Cancer Steering Committee (GCSC), she serves as a co-chair of the GCSC Ovarian Cancer Task Force and the NCI Ovarian Cancer Clinical Trials Planning Meeting. As such, she is guiding development of future NCI trials designed to push the field forward and expand the role of precision medicine in ovarian cancer.
It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.
CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Paula Anastasia, MN, RN, AOCN–has disclosed that she is on the speakers bureau for Genentech and Seagen. She is also on the Merck Advisory Board.
Jennifer Filipi, MSN, NP–has no relevant financial relationships to disclose in relation to the content of this activity.
Shannon N. Westin, MD, MPH–has disclosed that she receives a salary/employment from AstraZeneca, OncXerna Therapeutics Inc, and Roche/Genentech. She has ownership interest/stock or stock options in Bayer, Eisai, and Zentalis. She receives grants from Agenus, EQRx, ImmunoGen, and Merck. She receives research support from Clovis Oncology, Lilly, and Pfizer. She is on the speakers bureau for Cotinga Pharmaceuticals. She is an advisor or consultant for GlaxoSmithKline. She owns stock/shareholder (self managed) in Mereo and receives other financial or material support from Novartis.
Kristi Acker DNP, PhD, CRNP, FAANP–has no relevant financial relationships to disclose in relation to the content of this activity.
Susan H. Gitzinger, PharmD, MPA–has no relevant financial relationships to disclose in relation to the content of this activity.
Tina L. Trieu, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Jessica Hall–has no relevant financial relationships to disclose in relation to the content of this activity.
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity is designated for 1.5 contact hours.
Upon completion of an evaluation and credit request, statements of credit for nurses will be issued within 30 business days.
ONCC/ILNA Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. OCN®, AOCNP®, CBCN®, CPHON®, and BMTCN® nurses may apply 1.5 points in Care Continuum, Oncology Nursing Practice, Professional Practice/Performance, Symptom Management, and Treatment categories.
Disclaimer: ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.
- 1.50 ANCC
- 1.50 Participation